Genetically Engineered Cells for AAV Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The production of Adeno-Associated Virus (AAV) for gene therapy is hindered by the cytotoxic nature of genes like Rep, E2A, and E4, which complicates stable producer cell line development, leading to high costs and variability due to the need for large DNA and transfection reagent quantities and poor transfection efficiency.
Innovation Solution
The development of AAV production systems with inducible control of gene products, including cytostatic or cytotoxic genes, through stable integration of nucleic acid molecules encoding essential proteins like Rep52, Rep40, E2A, and VP1, linked to degradation domains or CRISPR/Cas systems for controlled expression, allowing for regulated protein production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If transient transfection of plasmids is used for AAV production, then viral production can be achieved, but large quantities of DNA and transfection reagent are required increasing cost and variability
Solution Approach 1:
The patent applies preliminary action by pre-integrating the AAV production gene set (Rep52/Rep40, DD-Rep78/DD-Rep68, DD-E2A, DD-E4Orf6, VARNA, VP1, VP2, VP3, AAP) into the host cell genome before production. This eliminates the need for transient transfection of large DNA quantities during viral production, as the genes are already stably present in the cell line.
Solution Approach 2:
The engineered cell line serves itself by maintaining stable integration of the AAV production genes in its genome. The cell autonomously produces the required viral proteins without requiring external DNA or transfection reagents, thereby reducing costs and variability associated with transient transfection processes.
2Productivity
If transient transfection is used, then AAV production can be performed, but poor transfection efficiency results in minimal transfected cells and increased variation
Solution Approach 1:
The patent performs preliminary integration of the AAV production gene set into the host cell genome through stable integration methods (random integration, targeted integration, or transposon-mediated integration). This ensures that nearly all cells in the population contain the necessary genes, eliminating the variability and low efficiency associated with transient transfection.
Solution Approach 2:
The engineered cell line autonomously maintains and expresses the AAV production genes through stable genomic integration, ensuring consistent protein production across the cell population without relying on external transfection reagents that cause variability and inefficiency.
3Productivity
If cytotoxic genes like Rep, E2A, and E4 are expressed, then AAV production is enabled, but cell viability is compromised due to cytotoxic nature
Solution Approach 1:
The patent applies dynamics by using inducible control mechanisms (such as chemically inducible promoters or degradation domains like FKBP or ecDHFR) to regulate the expression of cytotoxic genes. The genes are kept repressed under normal conditions to maintain cell viability, and only activated when viral production is required, thus balancing productivity with cell health.
Solution Approach 2:
The patent introduces intermediary control mechanisms such as degradation domains (FKBP, ecDHFR) and inducible promoters that mediate between the cytotoxic potential of Rep/E2A/E4 genes and the need for their expression. These intermediaries allow precise temporal and conditional control of gene expression, enabling viral production only when necessary while maintaining cell viability otherwise.
Data Source
AI summary
Disclosed herein are cell genetically engineered cell for AAV production. The genetically engineered cell comprises molecular systems for temporal control of expression of genes required for AAV production. Also disclosed herein are methods of using genetically engineered cells for AAV production.